Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
1.880
+0.030 (1.62%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Anebulo Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20
Selling, General & Admin
4.764.766.183.871.340.14
Research & Development
3.553.555.62.962.270.9
Operating Expenses
8.318.3111.786.833.611.04
Operating Income
-8.31-8.31-11.78-6.83-3.61-1.04
Interest Expense
-0.15-0.15---0.01-0.01
Interest & Investment Income
0.250.250.090.010-
Other Non Operating Income (Expenses)
0.010.01-0.04-0-26.63-
Pretax Income
-8.2-8.2-11.73-6.83-30.25-1.05
Net Income
-8.2-8.2-11.73-6.83-30.25-1.05
Preferred Dividends & Other Adjustments
----8.21-
Net Income to Common
-8.2-8.2-11.73-6.83-38.46-1.05
Shares Outstanding (Basic)
262625231412
Shares Outstanding (Diluted)
262625231412
Shares Change (YoY)
2.98%2.98%7.41%71.49%13.44%-
EPS (Basic)
-0.32-0.32-0.47-0.29-2.83-0.09
EPS (Diluted)
-0.32-0.32-0.47-0.29-2.83-0.09
Free Cash Flow
-8.09-8.09-9.68-5.44-4.87-0.9
Free Cash Flow Per Share
-0.31-0.31-0.39-0.23-0.36-0.08
EBIT
-8.31-8.31-11.78-6.83-3.61-1.04
Source: S&P Capital IQ. Standard template. Financial Sources.